Registration 333-291359
S-4/A · 2026-04-13 · 0001104659-26-042689
Terms from the governing filing for this registration; not a claim that the offering is open today.
Company research
CIK 2094256Updated Nov 22, 2026
17 filings on record · 8-K12B, 10-Q, 8-K, SC TO-I/A, SC TO-I, SP 15D2.
Items 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
Items 1.01, 9.01
Items 1.01, 8.01, 9.01
Items 3.03, 5.03, 9.01
Exhibit 99.1 CLYWEDOG THERAPEUTICS, INC. Condensed Consolidated Financial Statements As of June 30, 2026 and December 31, 2025 and for the Three and Six Months Ended June 30, 2026 and 2025 TABLE OF CONTENTS Condensed Consolidated Financial Statements Condensed Consolidated Balance Sheets as of June 30, 2026 (Unaudited) and December 31, 2025 F-3 Unaudited Condensed Consolidated Statements of Operations …
Read attachment ↗Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Introduction On September 29, 2025, Barinthus Biotherapeutics plc, a public limited company organized under the laws of England and Wales (“Barinthus Bio”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among Barinthus Bio, Clywedog Therapeutics Holdings, Inc. (formerly known as Beacon Topco, Inc.), a Delaware corporation and a direct wholly owned subsidiary of Barinthus Bio (“Topco”), Cdo…
Read attachment ↗Exhibit 99.1 FOR IMMEDIATE RELEASE Clywedog Therapeutics Announces Final Results from a Phase 1b Study of Balomenib in Type 2 Diabetes Patients, Showing Glycemic Improvement Sustained for Three Months After a Three-Week Course of Treatment o Placebo-adjusted mean HbA1c reduction of 0.77% at Week 12 (p<0.01) and 0.70% at Week 16 (p<0.05) — three months after the last dose — following only three weeks of balomenib treatment o Statistically signific…
Read attachment ↗EX-99.1 5 tm2530015d15_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Consent of Oppenheimer & Co. Inc. Oppenheimer & Co. Inc. (“Oppenheimer”) hereby consents to the inclusion of our opinion letter, dated September 29, 2025, to the Board of Directors (in its capacity as such) of Barinthus Biotherapeutic PLC (“Barinthus Bio”) included as Annex G, and to the references thereto under the captions “Summary - Opinion of Oppenheimer as Financial Advisor of Barinthus Bio,” “The Transactions - Background o…
Read attachment ↗Exhibit 99.1 Consent of Oppenheimer & Co. Inc. Oppenheimer & Co. Inc. (“Oppenheimer”) hereby consents to the inclusion of our opinion letter, dated September 29, 2025, to the Board of Directors (in its capacity as such) of Barinthus Biotherapeutic PLC (“Barinthus Bio”) included as Annex G, and to the references thereto under the captions “Summary - Opinion of Oppenheimer as Financial Advisor of Barinthus Bio,” “The Transactions - Background of the Transactions”, “The Transactions - Barinthus …
Read attachment ↗